Thiophanate Methyl

Thiophanate Methyl

SCHEMBL80466

COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC.c1ccc2[nH]c(-c3cscn3)nc2c1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 8/20 0.59
METAP2 P50579 5/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
KDM4E B2RXH2 3/20 0.59
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
TP53 P04637 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
ADORA3 P0DMS8 1/20 0.59
CYP2D6 P10635 1/20 0.59
TSHR P16473 1/20 0.59
CYP2C19 P33261 1/20 0.59
FKBP1A P62942 1/20 0.59
HIF1A Q16665 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
ALDH1A1 P00352 6/20 0.51
HPGD P15428 3/20 0.51
LMNA P02545 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiophanate SCHEMBL7196579 0.91 METAP1 (0.55) METAP1METAP2SMN1; SMN2KDM4ENPC1
Carbendazim SCHEMBL18131962 0.83 METAP1 (0.65) METAP1METAP2SMN1; SMN2KDM4ENPC1
Thiophanate Methyl SCHEMBL28140120 0.80 METAP1 (0.58) METAP1METAP2SMN1; SMN2KDM4ENPC1
Thiabendazole SCHEMBL675655 0.77 METAP1 (0.83) METAP1METAP2SMN1; SMN2KDM4ENPC1
Thiabendazole SCHEMBL30099775 0.77 METAP1 (0.83) METAP1METAP2SMN1; SMN2KDM4ENPC1
Thiabendazole SCHEMBL625588 0.77 METAP1 (1.00) METAP1METAP2SMN1; SMN2KDM4ENPC1
Thiabendazole SCHEMBL19842 0.77 METAP1 (1.00) METAP1METAP2SMN1; SMN2KDM4ENPC1
Thiabendazole SCHEMBL29370729 0.77 METAP1 (1.00) METAP1METAP2SMN1; SMN2KDM4ENPC1
Thiabendazole SCHEMBL28860081 0.76 METAP1 (0.81) METAP1METAP2SMN1; SMN2KDM4ENPC1
Thiabendazole SCHEMBL28170923 0.76 METAP1 (0.71) METAP1METAP2SMN1; SMN2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090117200-A1 Fungicide Composition Comprising a Phosphorous Acid Derivative, a Mandelamide Type Compound and a Further Fungicide Compound BAYER SAS (FR) 2009-05-07 US claimed
EP-1931200-A1 FUNGICIDE COMPOSITION COMPRISING AN ARYLAMIDINE DERIVATIVE AND TWO KNOWN FUNGICIDE COMPOUNDS Bayer CropScience AG (DE) 2008-06-18 EP claimed
EP-1898709-A1 FUNGICIDE COMPOSITION COMPRISING A PHOSPHOROUS ACID DERIVATIVE, A MANDELAMIDE TYPE COMPOUND AND A FURTHER FUNGICIDE COMPOUND Bayer CropScience S.A. (FR) 2008-03-19 EP claimed
WO-2007031507-A1 FUNGICIDE COMPOSITION COMPRISING AN ARYLAMIDINE DERIVATIVE AND TWO KNOWN FUNGICIDE COMPOUNDS BAYER CROPSCIENCE AG (DE) 2007-03-22 WO claimed
WO-2006136551-A1 FUNGICIDE COMPOSITION COMPRISING A PHOSPHOROUS ACID DERIVATIVE, A MANDELAMIDE TYPE COMPOUND AND A FURTHER FUNGICIDE COMPOUND BAYER CROPSCIENCE SA (FR) 2006-12-28 WO claimed
US-20240199709-A1 FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA SPOGEN BIOTECH INC (US) 2024-06-20 US disclosed
US-11905315-B2 Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria SPOGEN BIOTECH INC. (US) 2024-02-20 US disclosed
US-20210179672-A1 FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA GENISYS CREDIT UNION 2021-06-17 US disclosed
US-10836800-B2 Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria SPOGEN BIOTECH INC. (US) 2020-11-17 US disclosed
US-20200190149-A1 FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA GENISYS CREDIT UNION 2020-06-18 US disclosed
US-10407472-B2 Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria SPOGEN BIOTECH INC. (US) 2019-09-10 US disclosed
US-20180099999-A1 FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA GENISYS CREDIT UNION 2018-04-12 US disclosed
WO-2006108792-A1 NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2006-10-19 WO disclosed
WO-2006050772-A1 VINYLAMINOPYRAZOLE DERIVATIVES AS PESTICIDES MERIAL LTD. (US) 2006-05-18 WO disclosed
WO-2006008159-A1 A USE OF SULFONANILIDES AS AGRICULTURAL AND HORTICULTURAL FUNGICIDE BAYER CROPSCIENCE AG (DE) 2006-01-26 WO disclosed
WO-2006000312-A1 PESTICIDAL N-PHENYLPYRAZOLE DERIVATIVES MERIAL LTD. (US) 2006-01-05 WO disclosed
WO-2006000313-A1 N-PHENYLPYRAZOLE DERIVATIVES AS PESTICIDES MERIAL LTD. (US) 2006-01-05 WO disclosed
WO-2006000311-A1 1-ARYLPYRAZOLE DERIVATIVES PESTICIDAL AGENTS MERIAL LTD. (US) 2006-01-05 WO disclosed
WO-2006000315-A1 PESTICIDAL AGENTS ON THE BASIS OF 1- ARYL- AMINOPYRROL MERIAL LTD. (US) 2006-01-05 WO disclosed
WO-2006000314-A1 N-PHENYLPYRAZOLE DERIVATIVES AS PESTICIDES MERIAL LTD. (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090117200-A1 Fungicide Composition Comprising a Phosphorous Acid Derivative, a Mandelamide Type Compound and a Further Fungicide Compound PPA1, PPME1, MTAP METAP1 234/4885METAP2 182/4885SMN1; SMN2 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.